Alexander Diehl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alexander Diehl has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
K. Mann
10 shared publications- Bernhard Croissant
Department of Psychiatry and Psychotherapy, Teaching Hospital Sigmaringen, University of Tuebingen, Tuebingen, Germany
8 shared publications K Mann
6 shared publicationsD. Hermann
4 shared publications- Falk Kiefer
Department of Addictive Behavior and Addiction Medicine and
4 shared publications - Jochen Mutschler
Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Psychiatrische Universitätsklinik Zürich, Zürich, Switzerland
4 shared publications
Latest Publications
- 13 September 2013
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 46 (06) , A28
Clinical predictive factors to disulfiram treatment outcome in alcohol dependent patients - a cross-sectional study
The aim of this study was to determine possible predictive factors to disulfiram treatment outcome in patients with a long history of alcohol dependency. This study examined the association between sociodemographic, and clinical factors, and disulfiram treatment outcome in long-term alcohol dependent patients. A total of 46 alcohol dependent patients participating in the disulfiram treatment program in Mannheim have been assessed by standardized questionnaires (for example german version of the MOS support survey) in a cross-sectional study design. At the time of the assessment all subjects have already been treated with disulfiram for several weeks. We found significantly higher cumulative abstinence in patients with a current partnership. The assessed emotional, practical and cognitive social support was significantly higher in patients who were currently living in a partnership. Independently of other sociodemographic or clinical factors such as age, gender, work situation, comorbidities or severity of alcohol dependence, the patients who experienced increased functional social support showed an higher cumulative abstinence. Furthermore there is a significant positive correlation between the cognitive support and the educational level of the patients. The main predictive factor of a successfull disulfiram treatment outcome is a current partnership which implied an overall higher functional multidimensional social support.
- 13 September 2013
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 46 (06) , A28
Clinical predictive factors to disulfiram treatment outcome in alcohol dependent patients - a cross-sectional study
The aim of this study was to determine possible predictive factors to disulfiram treatment outcome in patients with a long history of alcohol dependency. This study examined the association between sociodemographic, and clinical factors, and disulfiram treatment outcome in long-term alcohol dependent patients. A total of 46 alcohol dependent patients participating in the disulfiram treatment program in Mannheim have been assessed by standardized questionnaires (for example german version of the MOS support survey) in a cross-sectional study design. At the time of the assessment all subjects have already been treated with disulfiram for several weeks. We found significantly higher cumulative abstinence in patients with a current partnership. The assessed emotional, practical and cognitive social support was significantly higher in patients who were currently living in a partnership. Independently of other sociodemographic or clinical factors such as age, gender, work situation, comorbidities or severity of alcohol dependence, the patients who experienced increased functional social support showed an higher cumulative abstinence. Furthermore there is a significant positive correlation between the cognitive support and the educational level of the patients. The main predictive factor of a successfull disulfiram treatment outcome is a current partnership which implied an overall higher functional multidimensional social support.
- 29 September 2011
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 44 (06) , A81
Experienced acetaldehyde-reaction is not associated with improved treatment response in patients treated with disulfiram
The major mode of action of disulfiram is assumed to be a psychological deterrence of an acetaldehyde-reaction following alcohol consumption. However it is still unclear whether patients need to experience an acetaldehyde-reaction with the help of a “test-drink” at the beginning of the therapy in order to achieve a better efficacy. Therefore, in this study, we test the hypothesis if an experienced acetaldehyde-reaction during the therapy with disulfiram predicts better treatment outcome in alcohol dependent patients. We evaluated outcome data of 46 patients treated with supervised disulfiram with experienced vs. not-experienced acetaldehyde-reaction. Alcohol consumption during outpatient disulfiram treatment was reported by 46% of the patients. Ninety % of these patients reported typical symptoms of an acetaldehyde-reaction. Comparing the course of abstinence rates, our results suggest that the experience of an acetaldehyde-reaction was not associated with any differences in treatment outcome, but with a significant earlier discontinuation of the therapy. This study supports the position that the experience of an acetaldehyde-reaction is not necessary for disulfiram's action and does not lead to a better treatment outcome. Hence, there is no evidence for the necessity of a “test-drink” before the initiation of a supervised disulfiram therapy.
- 29 September 2011
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 44 (06) , A81
Experienced acetaldehyde-reaction is not associated with improved treatment response in patients treated with disulfiram
The major mode of action of disulfiram is assumed to be a psychological deterrence of an acetaldehyde-reaction following alcohol consumption. However it is still unclear whether patients need to experience an acetaldehyde-reaction with the help of a “test-drink” at the beginning of the therapy in order to achieve a better efficacy. Therefore, in this study, we test the hypothesis if an experienced acetaldehyde-reaction during the therapy with disulfiram predicts better treatment outcome in alcohol dependent patients. We evaluated outcome data of 46 patients treated with supervised disulfiram with experienced vs. not-experienced acetaldehyde-reaction. Alcohol consumption during outpatient disulfiram treatment was reported by 46% of the patients. Ninety % of these patients reported typical symptoms of an acetaldehyde-reaction. Comparing the course of abstinence rates, our results suggest that the experience of an acetaldehyde-reaction was not associated with any differences in treatment outcome, but with a significant earlier discontinuation of the therapy. This study supports the position that the experience of an acetaldehyde-reaction is not necessary for disulfiram's action and does not lead to a better treatment outcome. Hence, there is no evidence for the necessity of a “test-drink” before the initiation of a supervised disulfiram therapy.
- 31 December 2010
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 25 (S1)
P03-201 - Quetiapine in alcohol relapse prevention - a case series
- 31 December 2010
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 25 (S1)
P03-201 - Quetiapine in alcohol relapse prevention - a case series
- 31 December 2010
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 25 (S1) , 1266
P03-200 - RCT: oxcarbazepine in alcohol relapse prevention
Results After withdrawal, time to severe relapse and time to first consumption of any ethanol by OXC patients was not longer than for ACP patients. Abstinent patients in both study groups showed significantly lower OCDS-G than relapsed patients. No undesired effects occurred when OXC patients consumed alcohol. While the current sample size clearly limits further conclusions from this pilot study, it is noteworthy that OXC is well tolerated. Thus, in medication-based relapse prevention, OXC could have the potential of a promising alternative for alcoholic patients unable to benefit from ACP or naltrexone or who suffer from affective lability. OXC certainly merits a larger placebo controlled trial.
- 31 December 2010
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 25 (S1) , 1266
P03-200 - RCT: oxcarbazepine in alcohol relapse prevention
Results After withdrawal, time to severe relapse and time to first consumption of any ethanol by OXC patients was not longer than for ACP patients. Abstinent patients in both study groups showed significantly lower OCDS-G than relapsed patients. No undesired effects occurred when OXC patients consumed alcohol. While the current sample size clearly limits further conclusions from this pilot study, it is noteworthy that OXC is well tolerated. Thus, in medication-based relapse prevention, OXC could have the potential of a promising alternative for alcoholic patients unable to benefit from ACP or naltrexone or who suffer from affective lability. OXC certainly merits a larger placebo controlled trial.
- 31 December 2010
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 25 (S1)
P03-199 - RCT: Quetiapine vs. placebo in alcohol relapse prevention. Rational, methods and preliminary results
- 31 December 2010
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 25 (S1)
P03-199 - RCT: Quetiapine vs. placebo in alcohol relapse prevention. Rational, methods and preliminary results
- Open Access
- 26 March 2010
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 45 (3) , 271-277
Why is Disulfiram Superior to Acamprosate in the Routine Clinical Setting? A Retrospective Long-Term Study in 353 Alcohol-Dependent Patients
Aims: To compare the long-term effectiveness of acamprosate (ACP) and disulfiram (DSF) in the treatment of alcohol dependence and their effectiveness in regard to patient characteristics, within a naturalistic outpatient treatment setting. Method: Retrospective data from 2002 to 2007 were analysed on 353 alcohol-dependent subjects in outpatient treatment, who, according to the patient’s and the clinician’s mutual decision, received either supervised DSF (with thrice-weekly appointments) or ACP (once-weekly appointments) following an inpatient alcohol detoxification treatment. Abstinence was assessed by alcohol breathalyzer, patients’ self-report, urine and serum analyses, and overall physicians’ rating. Results: Baseline data in terms of current addictive behaviour and course of disease differed between groups to the disadvantage of the DSF group; compared to the ACP group, subjects treated with DSF showed a longer duration of alcohol dependence, higher amounts of daily alcohol consumption and more alcohol detoxification treatments in their history. In follow-up, Kaplan–Meier survival analysis revealed significant differences between groups in the primary and secondary measures of outcome (P always Conclusions: This study supports the thesis that supervised DSF is an important component of alcoholism treatment, and it appears to be more effective than the treatment with ACP particularly in patients with a long duration of alcohol dependence.
- 26 March 2010
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 45 (3) , 271-277
Open AccessWhy is Disulfiram Superior to Acamprosate in the Routine Clinical Setting? A Retrospective Long-Term Study in 353 Alcohol-Dependent Patients
Aims: To compare the long-term effectiveness of acamprosate (ACP) and disulfiram (DSF) in the treatment of alcohol dependence and their effectiveness in regard to patient characteristics, within a naturalistic outpatient treatment setting. Method: Retrospective data from 2002 to 2007 were analysed on 353 alcohol-dependent subjects in outpatient treatment, who, according to the patient’s and the clinician’s mutual decision, received either supervised DSF (with thrice-weekly appointments) or ACP (once-weekly appointments) following an inpatient alcohol detoxification treatment. Abstinence was assessed by alcohol breathalyzer, patients’ self-report, urine and serum analyses, and overall physicians’ rating. Results: Baseline data in terms of current addictive behaviour and course of disease differed between groups to the disadvantage of the DSF group; compared to the ACP group, subjects treated with DSF showed a longer duration of alcohol dependence, higher amounts of daily alcohol consumption and more alcohol detoxification treatments in their history. In follow-up, Kaplan–Meier survival analysis revealed significant differences between groups in the primary and secondary measures of outcome (P always Conclusions: This study supports the thesis that supervised DSF is an important component of alcoholism treatment, and it appears to be more effective than the treatment with ACP particularly in patients with a long duration of alcohol dependence.
- 31 December 2009
- Published by Elsevier in Psychosomatics
- Vol. 50 (6) , 599-604
Consultation–Liaison Psychiatry in General Hospitals: Improvement in Physicians’ Detection Rates of Alcohol Use Disorders
- 31 December 2009
- Published by Elsevier in Psychosomatics
- Vol. 50 (6) , 599-604
Consultation–Liaison Psychiatry in General Hospitals: Improvement in Physicians’ Detection Rates of Alcohol Use Disorders
- 1 November 2009
- Published by Elsevier in Psychosomatics
- Vol. 50 (6) , 599-604
Consultation-Liaison Psychiatry in General Hospitals: Improvement in Physicians' Detection Rates of Alcohol Use Disorders
- 1 November 2009
- Published by Elsevier in Psychosomatics
- Vol. 50 (6) , 599-604
Consultation-Liaison Psychiatry in General Hospitals: Improvement in Physicians' Detection Rates of Alcohol Use Disorders
- 1 September 2009
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 42 (05) , 175-181
Oxcarbazepine in Combination with Tiaprid in Inpatient Alcohol-withdrawal – a RCT
Introduction: Oxcarbazepine (OXC), a derivative of Carbamazepine (CBZ), may represent a solution to metabolic and side effects of CBZ treatment due to the fact that renal excretion is its major route of elimination. The goal of the study is to compare the efficacy and tolerability of OXC/Tiaprid (TIA) combination therapy to the well established Clomethiazole (CLO) therapy in an inpatient setting. Methods: To investigate the efficacy of OXC/TIA in terms of lower alcohol withdrawal symptoms and better tolerability, 56 alcohol-dependent patients participated in a randomized open-label trial, where OXC/TIA and CLO treatments were compared. Results: Following admission, we observed that severity of alcohol withdrawal syndrome was comparable between OXC/TIA and CLO-patients. Overall tolerability was good. However, significantly more patients in the OXC/TIA-group (48.1%) displayed no AE compared to the CLO-group (24.1%). We found no significant differences between groups regarding total number of recorded adverse events (AEs). Discussion: OXC/TIA inpatient therapy proved to be as effective and participants demonstrated the same tolerance as with CLO. In medication-based alcohol withdrawal, OXC/TIA could have the potential to become a promising alternative for alcohol dependent patients unable to undergo inpatient withdrawal therapy with CLO. Our findings further indicate that it could be worthwhile testing OXC/TIA in alcohol withdrawal in daily care units and outpatient settings. This is an important question for national health care services, since outpatient therapy is more and more asked for as alternative to inpatient settings.
- 1 September 2009
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 42 (05) , 175-181
Oxcarbazepine in Combination with Tiaprid in Inpatient Alcohol-withdrawal – a RCT
Introduction: Oxcarbazepine (OXC), a derivative of Carbamazepine (CBZ), may represent a solution to metabolic and side effects of CBZ treatment due to the fact that renal excretion is its major route of elimination. The goal of the study is to compare the efficacy and tolerability of OXC/Tiaprid (TIA) combination therapy to the well established Clomethiazole (CLO) therapy in an inpatient setting. Methods: To investigate the efficacy of OXC/TIA in terms of lower alcohol withdrawal symptoms and better tolerability, 56 alcohol-dependent patients participated in a randomized open-label trial, where OXC/TIA and CLO treatments were compared. Results: Following admission, we observed that severity of alcohol withdrawal syndrome was comparable between OXC/TIA and CLO-patients. Overall tolerability was good. However, significantly more patients in the OXC/TIA-group (48.1%) displayed no AE compared to the CLO-group (24.1%). We found no significant differences between groups regarding total number of recorded adverse events (AEs). Discussion: OXC/TIA inpatient therapy proved to be as effective and participants demonstrated the same tolerance as with CLO. In medication-based alcohol withdrawal, OXC/TIA could have the potential to become a promising alternative for alcohol dependent patients unable to undergo inpatient withdrawal therapy with CLO. Our findings further indicate that it could be worthwhile testing OXC/TIA in alcohol withdrawal in daily care units and outpatient settings. This is an important question for national health care services, since outpatient therapy is more and more asked for as alternative to inpatient settings.
- 31 August 2009
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 42 (05) , A110
Disulfiram in the treatment of pathological gambling?
Aims: Pathological gambling and comorbide alcohol dependence are common occuring diseases, with serious consequences for social and mental health. Disulfiram is one of the proven drugs for alcohol dependence. It was shown recently, that Disulfiram is also effective in relapse prevention of cocaine addiction. In addition to its inhibiting effect of the acetaldehyde dehydrogenase (ADH), disulfiram inhibits the dopamine β-hydroxylase (DBH) and thereby augments dopamine and depletes norepinephrine concentrations in CNS in both, animals and humans. Inhibition of the DBH is suggested to be the responsible mechanism of disulfiram acting in cocaine addiction. Previous research indicates common neurochemical substrates for pathological gambling and cocaine addiction. This suggests that dopamine substrates may directly govern the reinforcement process in pathological gambling. Methods: In this report we now present the clinical data of a patient who was treated with disulfiram in our outpatient unit for addiction treatment due to existing alcohol dependence. The patient suffered also from severe pathological gambling. Results: Initialy we started to treat the patient with supervised disulfiram because of his alcohol dependence. During the treatment with disulfiram the patient's desire for gambling disappeared entirely and he has not gambled anymore since then. Conclusions: However, the exact mechnism of action by which disulfiram reduces urge to gamble is not fully unterstood, yet. Because craving is a key contributor to relapse, strategies aimed at modulate dopamine increases are likely to be therapeutically beneficial in gambling. Although uncontrolled case observations can only be interpreted with caution disulfiram seems to deserve further investigation and may hold the potential for preventing relapse in gamblers suffering from additional alcohol dependence.
- 31 August 2009
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 42 (05) , A110
Disulfiram in the treatment of pathological gambling?
Aims: Pathological gambling and comorbide alcohol dependence are common occuring diseases, with serious consequences for social and mental health. Disulfiram is one of the proven drugs for alcohol dependence. It was shown recently, that Disulfiram is also effective in relapse prevention of cocaine addiction. In addition to its inhibiting effect of the acetaldehyde dehydrogenase (ADH), disulfiram inhibits the dopamine β-hydroxylase (DBH) and thereby augments dopamine and depletes norepinephrine concentrations in CNS in both, animals and humans. Inhibition of the DBH is suggested to be the responsible mechanism of disulfiram acting in cocaine addiction. Previous research indicates common neurochemical substrates for pathological gambling and cocaine addiction. This suggests that dopamine substrates may directly govern the reinforcement process in pathological gambling. Methods: In this report we now present the clinical data of a patient who was treated with disulfiram in our outpatient unit for addiction treatment due to existing alcohol dependence. The patient suffered also from severe pathological gambling. Results: Initialy we started to treat the patient with supervised disulfiram because of his alcohol dependence. During the treatment with disulfiram the patient's desire for gambling disappeared entirely and he has not gambled anymore since then. Conclusions: However, the exact mechnism of action by which disulfiram reduces urge to gamble is not fully unterstood, yet. Because craving is a key contributor to relapse, strategies aimed at modulate dopamine increases are likely to be therapeutically beneficial in gambling. Although uncontrolled case observations can only be interpreted with caution disulfiram seems to deserve further investigation and may hold the potential for preventing relapse in gamblers suffering from additional alcohol dependence.